Abe, Rei J.
Abe, Jun-ichi
Nguyen, Minh T. H.
Olmsted-Davis, Elizabeth A.
Mamun, Abrar
Banerjee, Priyanka
Cooke, John P.
Fang, Longhou
Pownall, Henry
Le, Nhat-Tu
Funding for this research was provided by:
National Institutes of Health (R01HL133254, R01HL132155, R21AR077783, R01HL134740)
DOD Peer Reviewed Cancer Research Program (PR200305)
Article History
Accepted: 2 February 2022
First Online: 25 March 2022
Declarations
:
: This article does not contain any studies with human or animal subjects performed by any of the authors.
: LF reports the following patents planned, issued, or pending: (1) Compositions and methods for regulating angiogenesis and cholesterol and treating dyslipidemia, atherosclerosis, cancer, and inflammatory conditions (US20160115211A1); (2) compositions and methods for increasing lymphangiogenesis (Attorney Docket Number 10063-057WO1); (3) compositions and methods for treating neovascularization and ischemic retinopathies by targeting angiogenesis and cholesterol transport; and (4) Methods and compositions for treatment of aberrant hematopoiesis (Attorney Docket No. 16315-P002WO).JPC reports consulting fees from JanOne.The other authors declare that they have no conflict of interest.